Page 4«..3456..1020..»

Say Hello to Hydration With These Winter Beauty Essentials – Brit + Co

By daniellenierenberg

Transitional beauty can be a challenge. With shifting temperatures and weather, our hair and skin can feel dried out and dull, leaving our overall look (and feel) a little less than. But never fret, beauty babes! Ahead we've got our favorite new finds to keep you hydrated, moisturized, and looking luminous as heck all winter long and beyond!

Each & Every Worry-Free Deodorant ($15): Calling all sweaty Betty's, this 'Everlane of deodorants' is 2019's all-natural answer to your stinky woes. Made without aluminum, parabens, synthetic fragrances, gluten (yes, that's a thing), or baking soda, this cruelty-free stick comes in eight fab fragrances to keep you feeling dry and smelling fresh all day long.

On All Eyes On Me ($28): Instantly lift and cool those puffy, morning-after eyes with these slip-free eye gels. Packed with the good stuff like vitamin C, cucumber, and arnica and none of the bad, this travel-friendly 5-pack is ideal for your upcoming holiday adventures.

Kiehl's Avocado Nourishing Hydrating Mask ($45): What's better than avocado toast? Almost nothing. But this ultra-nourishing face mask is a close second. Rich and creamy, this fragrance-free formula takes just 15 minutes to give you the full, moisturized effects.

Maria Nila Silver Shampoo ($27): Summer may be gone, but your bright blonde doesn't have to go anywhere. Violet pigment and blackberry extract are the secrets to this 100% vegan and Swedish-made shampoo that's formulated to make your golden locks shine their lightest and brightest.

Alfie Firming Facial Serum ($64): Buh-bye pesky wrinkles! This serum does it all with the help of a few friends. Hyaluronic Acid, plant stem cells, and organic CBD are blended to firm up your face, hydrate lost moisture, improve blood flow, and reduce tension.

Kitsch Dalmatian Jasper Crystal Facial Roller ($24): ICYMI, gemstone rollers are all the rage right now, and we can see why. This Jasper beaut will gently massage away tension and stress to reduce wrinkles and help circulate blood.

Save Me From Chemical Conflict Tip To Hair Reboot ($78): Is your hair broken and therefore your life feels a little broken, too? Repair bleach damage and overprocessed locks with a scalp and hair treatment we can't stop raving about. Your radiant reboot begins NOW.

Milo New York Amber Fort Elixir Oud ($62+): A little facial oil can go a long way, especially when it's packed with vitamin C, alpha hydroxy acid, and Indian pink lotus flower. Brighter, smoother, more luminous skincare is here.

UMA Oils Flawlessly Firming Neck, Chest & Decolletage Serum ($105): Your skin deserves to feel smooth and firm no matter how old of a millennial you happen to be. Worth the extra buck, this antioxidant-rich serum is fast-absorbing and gives a more ageless appearance to your most delicate areas.

Tweezerman Lash Assist ($18): Lash on, lash off. From the pros who brought us a really good brow tweeze comes a one and done for your fake lashes. Seamlessly and precisely apply either individual or strip lashes for that glam effect you've always wanted sans stress!

Verb Curl Kit ($80): Calling all curly gals! This four-part kit is just what your locks will love. Clean, hydrate, restore, and define and keep those curls lookin' and feelin' healthy year-round.

RELATED: These Are the Best Everyday Face Sunscreens of 2019

Brit + Co may at times use affiliate links to promote products sold by others, but always offers genuine editorial recommendations.

Read the original:
Say Hello to Hydration With These Winter Beauty Essentials - Brit + Co

To Read More: Say Hello to Hydration With These Winter Beauty Essentials – Brit + Co
categoriaSkin Stem Cells commentoComments Off on Say Hello to Hydration With These Winter Beauty Essentials – Brit + Co | dataDecember 5th, 2019
Read All

15 Best Neck Creams (That Actually Work) – New Idea

By daniellenierenberg

RELATED: This brand new anti-ageing treatment is a game-changer

The neck is a delicate area thats easy to overlook, but it plays a big role in giving our face an attractive shape and profile. Over time, the skin may weaken from sun damage, dryness, and stress making us look much older. This is where firming neck creams come in handy! Here are some important active ingredients to look for in anti-aging products:

These products are packed with anti-wrinkle chemicals that tighten problem areas with regular use. Simply apply it with gentle motions after a shower and work it into your skin until fully absorbed. Pair it with your trusted eye cream and your skin will be thanking you!

If youre worried about the price, you can rest easy! Weve made sure to include a few budget options in our list for the savvy consumer.

Pros & Cons: This cream is made with organic ingredients and collagen to give your skin a supple glow! The downside is that it can be hard to find local stocks since its made in China.

Price: $AUD46.30

Buy It On: eBay

Pros & Cons: The combination of Hyaluronic Acid and creatine work together with Q10 coenzymes to regenerate new skin cells. A fair warning: some customers dont enjoy how the yellow colour of the pearls that stick to the skin.

Price: $AUD17.99

Buy It On: Amazon

Pros & Cons: This cream is made with aloe vera and Hyaluronic Acid, perfect for refining stubborn lines, wrinkles, and pigmentation on the neck. However, some people dont enjoy the grainy texture of the cream.

Price: $AUD52

Buy It On: Brickell Mens Products

Pros & Cons: Harnessing natures powerful vitamins, this cream uses botanical extracts to purge your skin of impurities. It works best for medium to dry skin, but could cause oily skin to break out.

Price: $AUD24.95

Buy It On: Swiss

Pros & Cons: This rich night cream is infused with Hyaluronic Acid and Retinol to replenish dull skin. It has lots of rave reviews for boasting visible results within a week, but the smell might be a little intense for some people.

Price: $AUD24.49

Buy It On: Amazon

Pros & Cons: Made with rosehip, olive, green coffee, and quinoa; this non-toxic, vegetarian cream brings out the best in your skin. But it may take a while to see results since it contains mild ingredients.

Price: $AUD16.95

Buy It On: Ebay

Pros & Cons: South Beach Skincare combines Vitamin C and Hyaluronic Acid with Retinol to create a paraben-free cream for all skin aging problems. Although its quite pricey, customers believe its worth every dollar!

Price: $AUD189

Buy It On: Life Cell Skin

Pros & Cons: This fragrance-free night cream evens out discolouration to give you a healthy glow, minimising stubborn imperfections with vitamins and minerals. Use it sparingly at night to avoid feeling greasy.

Price: $AUD20.99

Buy It On: Chemist Warehouse

Pros & Cons: Made with collagen and aloe vera, this cream repairs, hydrates, and protects your skin all day and night. Its the cheapest option available, so some customers think its too good to be true!

Price: $AUD5.26

Buy It: Ebay

Pros & Cons: Enriched with sunflower and green seaweed extracts, this light cream is easily absorbed by the skin for fast-acting results. Its great for all skin types, but some claim that they changed their formula recently.

Price: $AUD100

Buy It: Clarins

Pros & Cons: This cold cream works wonders on dry, flaky skin! Infused with organic Manuka honey from New Zealand, it locks moisture in to reduce pores and wrinkles. Apply sparingly to avoid getting sticky!

Price: $AUD40

Buy It On: Woolworths

Pros & Cons: Proven to be one of the top choices for middle-aged women, this cream uses Idebenone technology to target and repair areas damaged from harsh chemicals. Its quite costly, but it totally works!

Price: $AUD140

Buy It On: Myer

Pros & Cons: This cream is clinically-proven to fight saggy skin, discolouration, and visible signs of aging with amino acids and stem cell extracts. Just take it easy with application because the scent can be a bit overpowering.

Price: $AUD69.95

Buy It: NeoStrata

Pros & Cons: This tiny jar of plastic surgeon-approved cream is jam-packed with collagen, niacin, and complex amino acids. Its considered the holy grail for restoring the necks elastic texture, but it tends to run out fast!

Price: $AUD68

Buy It On: Sephora

Getting yourself a neck lift doesnt have to be drastic! Its all about keeping yourself moisturised and protected so you can look and feel younger at any age. Its time to get your cream on!

RELATED: Why the world can't stop talking about jade rollers

See more here:
15 Best Neck Creams (That Actually Work) - New Idea

To Read More: 15 Best Neck Creams (That Actually Work) – New Idea
categoriaSkin Stem Cells commentoComments Off on 15 Best Neck Creams (That Actually Work) – New Idea | dataDecember 5th, 2019
Read All

Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 – Wolf Mirror

By daniellenierenberg

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition. This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Continue reading here:
Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 - Wolf Mirror

To Read More: Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 – Wolf Mirror
categoriaSkin Stem Cells commentoComments Off on Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 – Wolf Mirror | dataDecember 5th, 2019
Read All

2019: the year gene therapy came of age – FRANCE 24

By daniellenierenberg

Washington (AFP)

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome.

Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy.

"I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency."

Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors."

The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured.

"This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

"But these results are really exciting."

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified.

But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

"It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

- Cures -

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

"Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster."

Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period."

"We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.

These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection.

"You cannot do this in a community hospital close to home," said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

- Bioterrorism -

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine.

Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process.

"That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations.

"It's very easy to do if you don't care about the consequences," Musunuru added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online.

"Not everyone is a biologist or scientist," she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops?

Charpentier thinks that technology generally tends to be used for the better.

"I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

2019 AFP

See more here:
2019: the year gene therapy came of age - FRANCE 24

To Read More: 2019: the year gene therapy came of age – FRANCE 24
categoriaBone Marrow Stem Cells commentoComments Off on 2019: the year gene therapy came of age – FRANCE 24 | dataDecember 5th, 2019
Read All

Bone Marrow Aspirate Concentrates Market is Anticipated to Expand at a CAGR of 5% from 2017 to 2025 – Drnewsindustry

By daniellenierenberg

The global bone marrow aspirate concentrates market was valued around US$ 130.0 Mn in 2016 is anticipated to register a stable CAGR of over 5.0% during forecast period of 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled Bone Marrow Aspirate Concentrates Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20172025.

Growth of the global bone marrow aspirate concentrates market is driven by increased prevalence of and incidences of orthopedic diseases, and sports injuries, along with high growth of the cosmetic surgery industry and increasing applications of the BMAC products in the cosmetic and orthopedic surgeries. The bone marrow aspirate concentrates market in Asia Pacific is expanding with a high potential to grow registering a CAGR above 6.0% on the backdrop of unmet clinical needs, rising geriatric population, large patient pool, favorable government regulations, development in health care sector, and increased focus on research and developmental activities.

Request a PDF Sample of Bone Marrow Aspirate Concentrates Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40451

Increase in incidences of Osteoarthritis on the backdrop of rising geriatric population to drive market growth

According to a collaborative survey conducted by the United Nations and the World Health Organization, 1.2 billion people in China are suffering from OA, of which more than 55% are aged 60 years or above. On the backdrop of such a huge patient base, there has been several developments in the field orthopedic surgery. Bone marrow-derived stem cell treatment is considered a promising and advanced therapy. It reduces the injury healing time in orthopedic diseases to five to six weeks from four to six months in case of surgery.

Reduction in the healing time is a factor likely to propel the Bone Marrow Aspirate Concentrates market during the forecast period. However, pain associated with the treatment, lack of product approval, and preference for alternative treatments are negatively affecting the market growth. Moreover, high investments in R&D and clinical trials, slow approval processes entailing sunken costs, and marginal returns on investment (RoI) for stakeholders are primary concerns faced by manufacturer further hampering growth of the market.

Rise in the Number of BMAC Assisted Procedures to Boost Growth of Bone Marrow Aspirate Concentrates Accessories Segment

The product type segment is fragmented into bone marrow aspirate concentrates systems and bone marrow aspirate concentrates accessories. The bone marrow aspirate concentrates accessories segment is anticipated to carry major share of the market on the backdrop of rise in number of BMAC assisted procedures. Cell therapies have been used extensively over the past decade for a variety of medical applications to restore cellular function and enhance quality of life. Owing to the differentiation property, stem cells are being used for repair and regeneration of bone. Moreover, increase in awareness about hygiene and risk of cross-contamination in developing countries such as Brazil, China and India are expected to increase the use of single-use Jamshidi needles for bone marrow stem cell procedures. This is likely to fuel the growth of the accessories segment in the near future.

Request for a Discount on Bone Marrow Aspirate Concentrates Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40451

Orthopedic Surgery Application to Dominate the Global Bone Marrow Aspirate Concentrates Market

The application segment of global bone marrow aspirate concentrates market is divided into orthopedic surgery, wound healing, chronic pain, peripheral vascular disease, dermatology, and others applications. Of which, orthopedic surgery segment is anticipated to dominate the market owing to rising geriatric population, and surge in incidences of osteoarthritis around the globe.

The dermatology segment is anticipated to expand at the highest CAGR of over 6.0% during forecast period of 2017 to 2025 owing to current boom in the industry, increase in disposable income, and technological advancements in the market. The utilization of the regenerative ability of fibroblasts and keratinocytes from human skin has formed new ways to develop cell-based therapies for patients. Moreover, capacity of bone marrow derived extra-cutaneous cells is being researched for its plasticity in regenerating skin; it is likely to lead to the future growth of cell therapies in dermatology.

Rise in Healthcare Expenditure to Fuel Growth of Hospitals & Clinics End-user Segment

In terms of end-users, market is divided into hospitals & clinics, pharmaceutical & biotechnology companies, Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs), and academic & research institutes. The hospitals & clinics segment dominated the bone marrow aspirate concentrates market in 2016. The trend is expected to continue during the forecast period. The hospitals & clinics segment is likely to be followed by the biotechnology & biopharmaceutical companies segment in terms of market share during the forecast period. The segment is anticipated to hold more than 8.0% of market share in 2016. Growth of the segment is attributed to increasing number of biotechnology companies and rising partnerships among the market players to expand global presence.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email: [emailprotected]Website: http://www.transparencymarketresearch.comBlog: https://theglobalhealthnews.com/

The rest is here:
Bone Marrow Aspirate Concentrates Market is Anticipated to Expand at a CAGR of 5% from 2017 to 2025 - Drnewsindustry

To Read More: Bone Marrow Aspirate Concentrates Market is Anticipated to Expand at a CAGR of 5% from 2017 to 2025 – Drnewsindustry
categoriaBone Marrow Stem Cells commentoComments Off on Bone Marrow Aspirate Concentrates Market is Anticipated to Expand at a CAGR of 5% from 2017 to 2025 – Drnewsindustry | dataDecember 5th, 2019
Read All

As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types…

By daniellenierenberg

A new business intelligence report released by Garner Insights with title Global Stem Cell Therapy Market Research Report 2019 that targets and provides comprehensive market analysis with prospects to 2024. The analysts of the study have garnered extensive research methodologies and data sources (i.e. Secondary & Primary Sources) in order to generate collective and useful information that delivers latest market undercurrents and industry trends.

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

Get a Sample PDF Report: https://www.garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#request-sample

Some of key competitors or manufacturers included in the study are: Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix),

If you are involved in the Global Stem Cell Therapy industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports, we can provide customization according to your requirement.

Market Segment by Type, covers: Autologous, Allogeneic

Market Segment by Applications, can be divided into: Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others,

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

What are the affecting elements that are made reference to in the report?

Market Scenario:The report further highlights the development trends in the global Stem Cell Therapy market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Key Market Highlights:The Stem Cell Therapy report gives a top to bottom examination on a portion of the key elements, involving income, cost, limit, limit usage rate, creation, generation rate, utilization, import/send out, supply/request, net, piece of the pie, CAGR, and gross edge. Furthermore, the report shows a far reaching investigation of the market development factors and their most recent patterns, alongside important market fragments and sub-portions.

Analytical Tools:The Global Stem Cell Therapy Market report incorporates the decisively examined and assessed information of the significant market members and their market scope utilizing various investigative devices. The diagnostic apparatuses incorporate Porters five powers examination, SWOT investigation, achievability study, and venture return investigation, which have been utilized to consider the development of the key players working in the market.

Get Discount on this Report: https://www.garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#discount

Some of the Points cover in Global Stem Cell Therapy Market Research Report is:

Chapter 1: Overview of Global Stem Cell Therapy Market (2019-2024) Definition Specifications Classification Applications Regions

Chapter 2: Market Competition by Players/Suppliers 2019 and 2024 Manufacturing Cost Structure Raw Material and Suppliers Manufacturing Process Industry Chain Structure. Continued

The main points which are answered and covered in this Report are-

What will be the total Stem Cell Therapy Market in the coming years till 2024?What will be the key factors which will be overall affecting the industry?What are the various challenges addressed?Which are the major companies included?

Thank You For Visiting Our Report : you can likewise get singular part astute segment or locale insightful report form like Asia, United States, Europe.

View Full Report@ https://garnerinsights.com/Global-Stem-Cell-Therapy-Market-2019-by-Company-Regions-Type-and-Application-Forecast-to-2024#description

See the original post here:
As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types...

To Read More: As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types…
categoriaBone Marrow Stem Cells commentoComments Off on As per new Study on Stem Cell Therapy Market 2019 Future Strategy, Analysis and Prediction by Leading Manufacturers, its Application and Types… | dataDecember 5th, 2019
Read All

First UK Clinical Trial Site Open for Recruitment of Diabetic Patients with Chronic Limb-Threatening Ischemia Using Novel Patient-Specific…

By daniellenierenberg

London, UK, 4 December 2019:The first UK clinical trial site for the treatment of diabetic patients with chronic limb-threatening ischemia (CLI) using a novel patient-specific regenerative therapy has opened for patient recruitment at the University Hospital of Wales in Cardiff. The site will be evaluating Rexgeneros REX-001 in two Phase III trials, codenamed the SALAMANDER trials. The trials are being led by Mr Ian Williams, a Consultant Vascular Surgeon and the Principal Investigator at the site.

The University Hospital of Wales is participating in the trials through a consortium, the Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC), part of the Advanced Therapy Treatment Centre Network (ATTC) which aims to bring pioneering advanced therapy medicinal products (ATMPs) to patients. THE MW-ATTC has been working in collaboration with the Cardiff & Vale University Health Board to progress the initiation of the two SALAMANDER trials and is planning to activate new clinical trial sites in the Midlands in England shortly.

CLI is a chronic disease and the most serious form of peripheral arterial disease (PAD), a common condition in which a build-up of fatty deposits in the arteries reduces the blood flow to the legs and feet. CLI is characterized by chronic ischemic at-rest pain, ulcers or gangrene in one or both legs. CLI is a common condition in Europe and the United States affecting 1-1.5% of the population aged over 401. It represents an area of high unmet medical need as there are currently no approved therapies that successfully treat the CLI patient population. Patients with CLI have a very negative prognosis. A year after initial diagnosis, around 12% of patients have had an amputation. Five years after diagnosis the situation is even worse with mortality at 50%, rising to 70% after ten years2.

REX-001 represents a new class of regenerative medicines. It is an autologous cell therapy manufactured using the patients own bone marrow and consists of immune cells (lymphocytes, monocytes and granulocytes) and progenitor cells involved in immune modulation and tissue regeneration. It is administered as a single dose within 4 days after collection of bone marrow cells.

Ian Williams, Consultant Vascular Surgeon and Principal Investigator commented,Chronic limb-threatening ischemia is a serious disease with severe consequences and limited treatment options. There is a high unmet need for novel and innovative therapiessuch as REX-001that have the potential to be a highly effective treatment and to reduce amputation and mortality rates amongst the patient population.

Chris Fegan, Consultant Haematologist, Cardiff and Vale University Health Board said, We have brought together many highly specialized teams from diabetes, surgery, radiology and stem cell transplantation to participate in the pioneering SALAMANDER study here at Cardiff and Vale, which we hope will revolutionize treatment options for patients with chronic limb-threatening ischemia.

Rexgenero, the company pioneering the development of REX-001, says that the experimental product has already demonstrated efficacy in Phase I/II studies. In the Phase II clinical trial, 82% of patients with non-healing ischemic ulcers were healed within the first 12 months after a single administration dose of REX-001.

Joe Dupere, CEO of Rexgenero added, Treating our first patient with REX-001 in the UK will be an important milestone for our Phase III program in diabetic patients with chronic-limb threatening ischemia, a severe condition with high unmet need. With clinical trial sites and manufacturing bases now open across multiple countries in Europe, we are one step closer to completion of the Phase III studies and potential regulatory and market approval for an innovative and much-needed product.

Rexgenero is planning to treat a total of 60 patients with CLI and rest pain and 78 patients with CLI and non-healing ischemic ulcers in two independent Phase III SALAMANDER trials in approximately 25 hospitals across Europe.In addition to the trial sites in the UK, Rexgenero is also recruiting patients for both trials at sites inSpain, Austria, Portugal, Poland, Hungary, the Netherlands and the Czech Republic.

For more information about the REX-001 Phase III SALAMANDER trials, and how to participate, please visit theclinical trial website.

References

ENDS

For further information, please contact:

At Rexgenero

For media enquiries (Rexgenero)

Joe Dupere, CEO+44 (0)20 3700 7480info@rexgenero.com

Instinctif PartnersAshley Tapp+44 (0)20 7866 7923Rexgenero@instinctif.com

At the University Hospital of Wales

Cardiff and University Health BoardCommunications Team+44 (0)29 2074 6381news@wales.nhs.uk

About Rexgenero

Rexgenero is a clinical-stage regenerative medicine company developing innovative cell-based therapies targeting serious diseases with unmet medical needs.

The Companys lead candidate, REX-001, is a highly innovative autologous cell therapy that is being studied in a Phase III clinical programme in patients with chronic limb-threatening ischemia (CLI) with diabetes, a poorly treated disease with a high risk of amputation and death. REX-001 has been shown to be effective in Phase I/II and Phase II trials, alleviating CLI in the majority of patients, offering the potential to increase the quality of life of CLI patients by reducing pain, alleviating ulcers, increasing mobility, improving sleep and reducing the need for amputation. Rexgenero is developing REX-001 in a range of indications and, pending approval, intends to launch and market this specialty product in major territories.

Rexgenero is a privately-owned company, which draws on an exceptional understanding of the fundamental science of cell therapies developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies.

The Company was founded in 2015 and is headquartered in London (UK) with R&D and manufacturing operations in Seville (Spain) and Frankfurt (Germany).

For more information, please visit:www.rexgenero.com

Connect with us: Twitter:@_Rexgenero; LinkedIn:https://www.linkedin.com/company/rexgenero-limited/

About the REX-001 Phase III SALAMANDER Trials

REX-001 has shown efficacy in 70% of patients in Phase I and I/II studies and is currently progressing through two Phase III SALAMANDER trials in Europe being conducted at approximately 30 sites, with plans to enrol a total of 138 patients. The trials are given the name SALAMANDER in reference to the amphibians ability to regenerate its tail and limbs.

ThePhase III studyin patients with Rutherford stage 4 CLI will assess the efficacy and safety of REX-001 with a primary endpoint of complete relief of ischemic rest pain.

ThePhase III studyin patients with Rutherford stage 5 CLI will assess the efficacy and safety with a primary endpoint of complete ulcer healing.

Amputation-free survival is included as a secondary endpoint in both studies. The trials are expected to produce interim analysis in early 2021 with full results expected later that year; all dependent on the speed of patient recruitment.

For more information about the REX-001 Phase III SALAMANDER trials, please visit:https://www.cli-treatment.com

About the Midlands and Wales Advanced Therapy Treatment Centre (MW-ATTC)

The Midlands and Wales Advanced Therapy Treatment Centre (MW-ATTC) consists of a large regional network with the necessary commercial and NHS infrastructure required to facilitate the delivery of advanced therapy treatments to patients. The centre includes a wide range of specialists in advanced therapy manufacturing including academic and commercial partners, logistics companies, specialists in clinical trial delivery and teams focussed on IT solutions and health economics.

For more information, please visit:https://www.theattcnetwork.co.uk/centres/midlands-wales

The ATTC Network Programme is a world-first, UK system of Advanced Therapy Treatment Centres (ATTC) operating within the NHS framework and coordinated by the Cell and Gene Therapy Catapult to address the unique and complex challenges of bringing pioneering advanced therapy medicinal products (ATMPs) to patients. The centres include Innovate Manchester Advanced Therapy Centre Hub (iMATCH), Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC, comprising Birmingham, Wales and Nottingham) and Northern Alliance Advanced Therapies Treatment Centre (NA-ATTC, comprising Scotland, Newcastle and Leeds).

The network is initially supported by the Industrial Challenge Strategy Fund with the aim to develop first-of-a-kind technologies for the manufacture of innovative medicines across areas including blindness, cancer, heart failure, liver disease, neurological conditions and rare paediatric diseases.

For more information, please visit:https://www.theattcnetwork.co.uk/

Read the original post:
First UK Clinical Trial Site Open for Recruitment of Diabetic Patients with Chronic Limb-Threatening Ischemia Using Novel Patient-Specific...

To Read More: First UK Clinical Trial Site Open for Recruitment of Diabetic Patients with Chronic Limb-Threatening Ischemia Using Novel Patient-Specific…
categoriaBone Marrow Stem Cells commentoComments Off on First UK Clinical Trial Site Open for Recruitment of Diabetic Patients with Chronic Limb-Threatening Ischemia Using Novel Patient-Specific… | dataDecember 5th, 2019
Read All

Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 – 2025 – The Market Expedition

By daniellenierenberg

Global Stem Cell Therapy Market Analysis

The recent report published by TMRR on the global Stem Cell Therapy market is an in-depth analysis of the overall prospects of the Stem Cell Therapy market in the upcoming years. The data collected from credible primary and secondary sources is accurately represented in the report backed up by relevant figures, graphs, and tables. The report includes a quantitative and qualitative analysis of the various aspects of the market by collecting data from the key participants in the Stem Cell Therapy market value chain.

The report reveals that the global Stem Cell Therapy market is set to grow at a CAGR of ~XX% over the forecast period (2019-2029) and surpass the value of ~US$XX by the end of 2029. The presented study also includes a thorough analysis of the micro and macroeconomic factors, regulatory framework, and current trends that are expected to influence the growth of the Stem Cell Therapy market during the assessment period.

Reports are available at cut-down rates for new customers! Offer expires soon!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

Vital Information Enclosed in the Stem Cell Therapy Market Report:

Important Queries Addressed in the Report

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

Stem Cell Therapy Market Segmentation

The market study put forward by TMRR segments the global Stem Cell Therapy market to offer a microscopic understanding of the various aspects of the Stem Cell Therapy market. The Stem Cell Therapy market is segmented on the basis of region, product type, end-user, and more.

The study offers a Y-o-Y growth projection of each market segment and sub-segment over the stipulated timeframe of the study.

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Why Buy from TMRR?

Read the rest here:
Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 - 2025 - The Market Expedition

To Read More: Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 – 2025 – The Market Expedition
categoriaBone Marrow Stem Cells commentoComments Off on Stem Cell Therapy Market Size, Share, Trends, and Opportunity Analysis by 2017 – 2025 – The Market Expedition | dataDecember 5th, 2019
Read All

Scientists develop artificial nerve cells which behave just like real cells – CNET

By daniellenierenberg

The tiny artificial nerve cell fits on a fingertip.

Scientists have built tiny silicon microchips, small enough to fit on a fingertip, which are "nearly identical" to biological nerve cells present in the human body. The research team suggests the low-power cells-on-a-chip could be used in bio-electronic devices and implants, providing a new way to combat diseases affecting the nervous system, such as Alzheimer's, or spinal cord injury.

Nerve cells, or neurons, are present throughout the brain and the nervous system and rapidly send electrical signals through their long, spindly arms, relaying information from brain to body and back. Their signalling activities require ion channels that convert mechanical or chemical signals into electrical ones. It's a complex dance underlying all our nerve impulses -- but that complexity has made it difficult to unravel how cells respond to certain stimuli.

"Until now neurons have been like black boxes, but we have managed to open the black box and peer inside," said Alain Nogaret, a physicist at the University of Bath and co-author of the study, in a press release. "Our work is paradigm changing because it provides a robust method to reproduce the electrical properties of real neurons in minute detail."

The new study,published in the journal Nature Communications on Tuesday, details the breakthrough technology which reproduces the electrical properties of a neuron on the tiny chip. The team were able to replicate the dynamics of individual nerve cells in the brain required for memory ("hippocampal neurons") and those required for breathing ("respiratory neurons"). The chips have a number of synthetic ion channels, which are responsible for the electrical impulses in biological cells.

Comparing the signals to those found in rat hippocampal neurons and rat brain stem neurons, the research team subjected their chip to 60 different stimulation protocols and modeled the responses, finding each time the chip was able to recapitulate responses seen in real cells.

While the study shows promise for potential bio-medical implants in the future, the authors note that other features of nerve cells will need to be considered.

The chip acts like a single cell, but nerve cells are complex beasts with branching arms, known as dendrites, responsible for propagating signals from cell to cell. The team suggests their model allows for the "complete dynamics of a biological neuron" to be placed on the chip, while noting a second compartment may need to be added that could describe the active properties of dendrites.

Read the original:
Scientists develop artificial nerve cells which behave just like real cells - CNET

To Read More: Scientists develop artificial nerve cells which behave just like real cells – CNET
categoriaSpinal Cord Stem Cells commentoComments Off on Scientists develop artificial nerve cells which behave just like real cells – CNET | dataDecember 3rd, 2019
Read All

Paralyzed survivor of Humboldt Broncos crash at a loss for words over progress since spinal surgery – The Globe and Mail

By daniellenierenberg

Ryan Straschnitzki sits in a hockey sled while he does physiotherapy in Bangkok, Thailand after spinal surgery.

Tom Straschnitzki/The Canadian Press

A hockey player paralyzed in the Humboldt Broncos bus crash says he is thrilled with the progress hes made since receiving spinal surgery in Thailand a month ago.

Doctors implanted an epidural stimulator in Ryan Straschnitzkis spine, and one week later injected stem cells above and below the injury to try to reverse some of the damage.

The 20-year-old has just a week to go before returning home to Airdrie, Alta.

Story continues below advertisement

Its been progressively getting better and harder at the same time, which is good. They put me through a good sweat, doing a couple of laps around the buildings. Its good work, Mr. Straschnitzki said in an interview from Bangkok with The Canadian Press.

One video of his rehab shows him straightening a leg. In another, he is strapped into a harness as physiotherapists slowly help him walk with the use of a wheeled machine.

I was at a loss for words. I was really shocked and excited at the same time. It kind of scared me a little bit, but again, it was pretty excited, Mr. Straschnitzki said.

I dont remember being that tall.

He said he felt all sorts of emotions when he took his first steps since climbing aboard the Broncos hockey bus on April 6, 2018.

It gave me kind of a shock and brought back obviously a lot of memories ... [including] all the sports activities I was involved in.

Mr. Straschnitzki was one of 13 players injured when an inexperienced truck driver blew through a stop sign and into the path of the Saskatchewan junior teams bus. Sixteen others on the bus would die.

Story continues below advertisement

Mr. Straschnitzki, who was paralyzed from the chest down, isnt expecting a cure, but hopes the implant will restore some muscle movement.

Tom Straschnitzki, the young mans father, said the only downside is that his son is enduring spasms after using muscles that havent been working for the past 19 months.

Hes getting pain where he never had before, which is a good thing, but it takes months for it to kick in.

Tom Straschnitzki said the best part of the journey has been watching his son react to the changes hes experiencing.

When he took his first steps on his own and he controlled it ... he was pretty revved.

The surgery can cost up to $100,000 and isnt covered by public health care or insurance, because the epidural procedure has not been approved by Health Canada. The Straschnitzki family is paying for it, but is angry the treatment isnt available here.

Story continues below advertisement

Health Canada says it has licensed spinal-cord stimulators but only for pain relief.

The department has not licensed a spinal-cord stimulator device for regaining motor skills or sensory functions following spinal injuries, nor received an application for this intended use as of yet, Health Canada spokesman Geoffroy Legault-Thivierge wrote in an email.

Ryan Straschnitzki, who is hoping to make the Canadian sledge-hockey team and compete in the Olympics, took his sled with him to Thailand and has been sitting in it as part of his rehab.

Its supposed to help me with more balance, so when Im on the ice Im not falling over as easily.

Hes finally been cleared to return to the ice in Bangkok later this week.

Ive been itching to get out there and I cant wait.

Visit link:
Paralyzed survivor of Humboldt Broncos crash at a loss for words over progress since spinal surgery - The Globe and Mail

To Read More: Paralyzed survivor of Humboldt Broncos crash at a loss for words over progress since spinal surgery – The Globe and Mail
categoriaSpinal Cord Stem Cells commentoComments Off on Paralyzed survivor of Humboldt Broncos crash at a loss for words over progress since spinal surgery – The Globe and Mail | dataDecember 3rd, 2019
Read All

Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 – News Description

By daniellenierenberg

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market areSTEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Request Sample of Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.

Request for a Discount on Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comResearch Blog:https://theglobalhealthnews.com/

Read the rest here:
Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description

To Read More: Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 – News Description
categoriaSpinal Cord Stem Cells commentoComments Off on Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 – News Description | dataDecember 3rd, 2019
Read All

Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 – Statsflash

By daniellenierenberg

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market areSTEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Request Sample of Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.

Request for a Discount on Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comResearch Blog:https://theglobalhealthnews.com/

See the rest here:
Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 - Statsflash

To Read More: Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 – Statsflash
categoriaSpinal Cord Stem Cells commentoComments Off on Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 – Statsflash | dataDecember 3rd, 2019
Read All

Global Cell Therapy Processing Market Growth, Demand, Industry Verticals, and Forecast upto 2022 – News Description

By daniellenierenberg

TheCell Therapy Processing marketreport [6 Year Forecast 2016-2022] focuses on Major Leading Industry Players, providing info likeCell Therapy Processing product scope, market overview, market opportunities, market driving force and market risks.Profile the top manufacturers of Cell Therapy Processing, with sales, revenue and globalmarket share ofCell Therapy Processingare analyzed emphatically bylandscape contrastandspeak to info.Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Cell Therapy Processing marketbusiness development trends and selling channelssquare measure analyzed. From a global perspective, It also represents overall Cell Therapy Processing industry size by analyzingqualitative insights and historical data.

KNOW MORE WITH FREE SAMPLE STUDY @https://www.researchmoz.us/enquiry.php?type=S&repid=1692341

Summary

There are numerous indications that can be cured using cell therapies, and with increased R&D activities for cell therapies, the number of therapeutic uses is anticipated to increase in the near future. Some of the indications under investigation for the treatment using cell therapy are cerebral disorders such as Parkinsons disease and Alzheimers disease, and also cardiovascular disease. Cardiovascular disease could be treated using cell therapies with the aim to restore normal heart functions. Moreover, many studies are undergoing in the attempt to improve the safety and efficacy in treatment of different malignancies. Cell therapy could also be used to cure metabolic disorder such as diabetes mellitus type 1 where there is lack of insulin production in the patient. Researchers are also trying to restore normal liver and kidney function by introducing modified cells of respective origins. Presently, cell therapy could be a promising technique for the treatment of numerous conditions such as orthopedic, oncology, neurological and variety of autoimmune diseases. The increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies is anticipated to drive the markets growth in the near future. In addition, improved understanding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells offers lucrative opportunities for the cell therapy processing markets growth. The rising significance of stem cell therapies provides further understanding of lung biology and repair after lung injury, and further a sound scientific basis for therapeutic use of cell therapies and bioengineering approaches in the treatment of lung diseases.

Report Scope:

This research report presents an in-depth analysis of the global cell therapy processing market by offering type, application and geographic regional markets. The report includes key inhibitors that affect various factors that help in growth of cell therapy processing. The report discusses the role of supply chain members from manufacturers to researchers. The report analyzes key companies operating in the global cell therapy processing market. In-depth patent analysis in the report will provide extensive technological trends across years and regions such as North America, Europe, Asia-Pacific and ROW.

The cell therapy processing market is mainly segmented into three major components: offering type, application and region. Based on offering type, the market is segmented into products (cell lines, instruments, among others), services (product design, process design, among others) and software (enabling software). Based on application, the market is categorized into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair, cancer and others. The market is segmented by region into North America, Europe, Asia-Pacific and the ROW.

The cell therapy processing market is mainly segmented into three major components: offering type, application and region. Based on offering type, the market is segmented into products (cell lines, instruments, among others), services (product design, process design, among others) and software (enabling software). Based on application, the market is categorized into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair, cancer and others. The market is segmented by region into North America, Europe, Asia-Pacific and the ROW.

Interested in Report: Make an Enquiry to Our Expert @https://www.researchmoz.us/enquiry.php?type=E&repid=1692341

Report Includes:

40 data tables and 25 additional tables

An overview of the global market for cell therapy processing technologies

Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022

Analysis of the market by technology, application, and region

An outline of the present state of applications of rainwater harvesting

Descriptions of trends in price and price-performance and other factors, including demand in the market

Profiles of key companies in the market, including Biotime Inc., Cell Design Labs., Flodesign Sonics, Lonza Group Ltd. and Sanbio Co. Ltd.

Contact Us:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074Toll Free: 866-997-4948 (US-CANADA)Email:[emailprotected]Follow us on LinkedIn @http://bit.ly/2RtaFUo

Follow us on Blogger @https://marketnews-24.blogspot.com/

Visit link:
Global Cell Therapy Processing Market Growth, Demand, Industry Verticals, and Forecast upto 2022 - News Description

To Read More: Global Cell Therapy Processing Market Growth, Demand, Industry Verticals, and Forecast upto 2022 – News Description
categoriaIPS Cell Therapy commentoComments Off on Global Cell Therapy Processing Market Growth, Demand, Industry Verticals, and Forecast upto 2022 – News Description | dataDecember 3rd, 2019
Read All

Fat grafting improves range of motion in limbs damaged by radiation therapy – Yahoo Finance

By daniellenierenberg

A new study released today in STEM CELLS outlines how fat grafting - which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup - also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

DURHAM, N.C., Dec. 3, 2019 /PRNewswire-PRWeb/ --A new study released today in STEM CELLS outlines how fat grafting which previous studies have shown can reduce and even reverse fibrosis (scar tissue) buildup also improves the range of motion of the affected limb. The study, conducted by researchers at Stanford University School of Medicine, was conducted on mice.

The tumor-destroying capabilities of radiation therapy can be a life saver for a person suffering from cancer. But it's a therapy that has several unwanted side effects, too, including causing substantial damage not just to cancerous cells, but any healthy tissue in its path. Over time, fibrosis builds up in the treated area which, in the case of an arm, shoulder, or leg, for example, can lead to painful contractures that significantly limit extensibility and negatively impact the person's quality of life.

The Stanford team irradiated the right hind legs of subject mice, which resulted in chronic fibrosis and limb contracture. Four weeks later, the irradiated limbs of one group of the mice were injected with fat enriched with stromal vascular cells (SVCs). These potent cells already naturally exist in fat, but supplementation of fat with additional SVCs enhances its regenerative capabilities. A second group was injected with fat only, a third group with saline and a fourth group received no injections, for comparison. The animals' ability to extend their limb was then measured at baseline and every two weeks for a 12-week period. At the end of the 12 weeks, the hind limb skin underwent histological analysis and biomechanical strength testing.

"Each animal showed significant reduction in its limb extension ability due to the radiation, but this was progressively rescued by fat grafting," reported corresponding author Derrick C. Wan, M.D., FACS. Fat grafting also reduced skin stiffness and reversed the radiation-induced histological changes in the skin.

"The greatest benefits were found in mice injected with fat enriched with SVCs," Dr. Wan added. "SVCs are easily obtained through liposuction and can be coaxed into different tissue types, where they can support neovascularization, replace cells and repair injured issue.

"Our study showed the ability of fat to improve mobility as well as vascularity and appearance," he continued. "We think this holds enormous clinical potential especially given that adipose tissue is abundant and can be easily collected from the patients themselves and underscores an attractive approach to address challenging soft tissue fibrosis in patients following radiation therapy."

Furthermore, said co-author and world-renowned breast reconstructive expert Arash Momeni, M.D., FACS, "Our observations are potentially translatable to a variety of challenging clinical scenarios. Being able to reverse radiation-induced effects holds promise to substantially improve clinical outcomes in implant-based as well as autologous breast reconstruction. The study findings are indeed encouraging as they could offer patients novel treatment modalities for debility clinical conditions.

"Excessive scarring is a challenging problem that is associated with a variety of clinical conditions, such as burn injuries, tendon lacerations, etc. The potential to improve outcomes based on treatment modalities derived from our research is indeed exciting," Dr. Momeni added.

"Skin and soft tissue scarring and fibrosis are well-established problems after radiation. The current study, showing that human fat grafting can normalize the collagen networks and improve tissue elasticity in immune deficient mice, provides molecular evidence for how fat grafting functions," said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. "The studies indicate that, with the appropriate regulatory approvals, autologous fat grafting could potentially also help human patients recover from radiation-induced tissue fibrosis."

The full article, "Fat grafting rescues radiation-induced joint contracture," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/stem.3115.

Story continues

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

SOURCE STEM CELLS

Visit link:
Fat grafting improves range of motion in limbs damaged by radiation therapy - Yahoo Finance

To Read More: Fat grafting improves range of motion in limbs damaged by radiation therapy – Yahoo Finance
categoriaSkin Stem Cells commentoComments Off on Fat grafting improves range of motion in limbs damaged by radiation therapy – Yahoo Finance | dataDecember 3rd, 2019
Read All

Dr Sister Ltd Offers Effective Skin Treatments to Both Men and Women – The News Front

By daniellenierenberg

Dr Sister Ltd continues to offer effective skin treatments to both men and women, and they have been doing this for over 45 years now. Doctor Sister provides a comprehensive portfolio of treatments while at the same time delivering natural-looking, regenerative and enhancing results for the face and body. They are big believers in helping slow down the ageing process for each client, as of course, they are unable to stop time for you.

At Dr Sister Ltd, you can be treated by a professional doctor that trains other practitioners. Dr Sisterhimself has introduced over ten ground-breaking treatments to the UK market, along with eight published books, many articles in international peer reviews medical journals and general press, as well as being one of UKs and Europes leading lecturer and trainer in the field of Aesthetic Medicine.

The treatments offered by Dr Sister Ltd are non-invasive so there is no surgery and no downtime. Some of the skin treatments on offer at Dr Sister Ltd include the following; mini face lift, non-surgical face lift, vampire facial, PRP treatment and PRP injection. That is not an exhaustive list and he is also a renowned hormonal expert.

Dr. Sister has perfected safe, effective, natural-looking treatments, which has made him a worldwide expert and teacher in regenerative and innovative procedures such as Dracula PRP, Mint Lift including the new Stem Cell Facelift.

The PRP treatment (Dr. Sister has his own superior trademarked version called Dracula Therapy) may be unfamiliar to some clients. Dr Sister explains the procedure in great detail on their site. APRP treatment is a powerful anti-ageing treatment that involves using your blood as an injectable treatment (PRP Injection). Dr Daniel Sister was the first to introduce the treatment into the UK, and now he calls it Dracula Therapy.

With the Dracula Therapy or vampire facial, you will notice results within 3-4 weeks, and often only one PRP injection is required. However, the treatment may need to be repeated every 2-6 months because of the on-going ageing process.

The PRP injections generally appeal to patients looking for a more natural approach to facial rejuvenation, which is the rejuvenation process of using their cells. This treatment does not use synthetic fillers or animal products and has no risks or side effects.

At Dr Sister Ltd, they are well known for their aesthetic treatments, in particular, the MINT lift and Dr Sister is the training partner for the MINT lift. It is a PDO thread lift that offers exceptional results. Dr. Sister has been particularly impressed by the results as it provides an immediate and obvious lift, which many of his patients are looking for.

Dr Sister Ltd also mentions that local anaesthetic is used making the procedure pain free, and patients generally return to work and usual activities the following day. There are many benefits such as soft tissue lifting, instant lift, results lasting around 18 months.

If you would like to find out more about the treatments on offer at Dr Sister Ltd, there are many ways to get in touch. You can email press@drdanielsister.com your query, and they will get back to you as soon as possible, or you can go online to their website at https://drdanielsister.com. On their site, you will find all the information about the top treatments, fees, testimonials, and Dr Sister Ltd.

Source:https://thenewsfront.com/dr-sister-ltd-offers-effective-skin-treatments-to-both-men-and-women/

Here is the original post:
Dr Sister Ltd Offers Effective Skin Treatments to Both Men and Women - The News Front

To Read More: Dr Sister Ltd Offers Effective Skin Treatments to Both Men and Women – The News Front
categoriaSkin Stem Cells commentoComments Off on Dr Sister Ltd Offers Effective Skin Treatments to Both Men and Women – The News Front | dataDecember 3rd, 2019
Read All

Induced Pluripotent Stem Cells Market To Register High Revenue Growthat 7% CAGR Throughout 2018 to 2026 – Kentucky Reports

By daniellenierenberg

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition. This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

The rest is here:
Induced Pluripotent Stem Cells Market To Register High Revenue Growthat 7% CAGR Throughout 2018 to 2026 - Kentucky Reports

To Read More: Induced Pluripotent Stem Cells Market To Register High Revenue Growthat 7% CAGR Throughout 2018 to 2026 – Kentucky Reports
categoriaSkin Stem Cells commentoComments Off on Induced Pluripotent Stem Cells Market To Register High Revenue Growthat 7% CAGR Throughout 2018 to 2026 – Kentucky Reports | dataDecember 3rd, 2019
Read All

100 greatest innovations of 2019: Best of What’s New – Popular Science

By daniellenierenberg

Within days of giving birth, a womans estrogen and progesterone levels quickly drop, leading to chemical changes in the brain that might give rise to shifts in mood. In fact, as many as three in four mothers experience symptoms of depression soon after childbirth. But for one in nine mothers, those symptoms result in a more serious, longer-lasting, and potentially life-threatening condition known as postpartum depression. The disorder, which manifests as a significant change in mood within hours to weeks of giving birth, is the most common complication of pregnancy. Currently, the depression drugs used to treat it take weeks to months to kick intime that new mothers (and their infants) cant afford. Zulresso is the first FDA-approved medication designed to tackle postpartum depression, and it does so at speed. The drug is a synthetic form of allopregnanolone, a hormone that dampens neural activity and eases depression symptoms when estrogen and progesterone levels dip. In double-blind control studies run by the creators at Sage Therapeutics, Zulresso worked within 60 hours. Right now, the drug is administered via a 60-hour intravenous infusion (common among new medicines), but alternative treatments, including a pill form, are currently in clinical trials.

Continue reading here:
100 greatest innovations of 2019: Best of What's New - Popular Science

To Read More: 100 greatest innovations of 2019: Best of What’s New – Popular Science
categoriaSkin Stem Cells commentoComments Off on 100 greatest innovations of 2019: Best of What’s New – Popular Science | dataDecember 3rd, 2019
Read All

Professor Recognized For Cardiac Regeneration Research – WPI News

By daniellenierenberg

Glenn Gaudette, William Smith Deans Professor of Biomedical Engineering at Worcester Polytechnic Institute (WPI), has been named a fellow of theNational Academy of Inventors(NAI), the organization announced today. Gaudette is the founding director of the WPI Myocardial Regeneration Lab, where he has pioneered the use of plants as scaffoldingfor heart regeneration.

The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society. Election to NAI Fellow is the highest professional distinction accorded solely to academic inventors.

I am honored and humbled to be selected as a Fellow of the NAI. This prestigious recognition is a reflection of amazing collaborators, fantastic students, risk-taking funding organizations and a supportive family that I have been fortunate to benefit from, said Gaudette. Today, significant engineering and science advancements require a focus on creating value for society, work that flourishes in an open and collaborative environment like the one I enjoy at WPI.

As director of the Myocardial Regeneration Lab, Gaudette focuses broadly on cardiovascular regeneration techniques, but more specifically on developing better ways to deliver cells to damaged myocardium as well as better techniques to analyze cardiac mechanics. He has authored over 75 publications, including a co-edited book on cardiovascular regeneration, has four issued patents, and founded a company based on the technology developed in his laboratory. His research, which is supported by the National Institutes of Health and the National Science Foundation, aims to develop a treatment for the millions of Americans suffering from myocardial infarction and other cardiovascular diseases.

As a member of the NAI 2019 Fellows, Gaudette joins 168 educators and researchers representing 136 universities and governmental and nonprofit research institutes worldwide. Collectively, they hold over 3,500 issued U.S. patents. Among the 2019 Fellows are six recipients of the U.S. National Medal of Technology & Innovation or U.S. National Medal of Science and four Nobel Laureates, as well as recipients of other honors and distinctions. Their collective body of research covers a range of scientific disciplines including neurobehavioral sciences, horticulture, photonics and nanomedicine.

To date, NAI Fellows hold more than 41,500 issued U.S. patents, which have generated over 11,000 licensed technologies and companies, and created more than 36 million jobs. In addition, over $1.6 trillion in revenue has been generated based on NAI Fellow discoveries.

On April 10, 2020, the 2019 NAI Fellows will be inducted at the Heard Museum in Phoenix, Arizona as part of the Ninth Annual NAI Meeting. Laura A. Peter, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office (USPTO),will provide the keynote address for the induction ceremony. At the ceremony, Fellows will be formally inducted by Peter and NAI President Paul R. Sanberg in recognition of their outstanding achievements.

In addition to being named an NAI Fellow, Gaudette is a Fellow of the American Institute for Medical and Biological Engineering. His teams research usingspinach leavesas scaffolds for growing human heart cells has been featured by media outlets throughout the world, including the BBC, theWashington Post,and Time.com. The work was named one of the top medical breakthroughs of the year byBoston Magazineand was the seventh most popular story of 2017 inNational Geographic. He has also worked on a novel technology using fibrin sutures to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack.Outside the lab, Gaudette teaches biomedical engineering design and innovation, biomechanics and physiology. He promotes the development of the entrepreneurial mindset in his students through support provided by the Kern Family Foundationand serves as the director of the Value Creation Initiative at WPI.In 2015, he was named Faculty Member of the Year by the Kern Entrepreneurial Engineering Network (KEEN).

Link:
Professor Recognized For Cardiac Regeneration Research - WPI News

To Read More: Professor Recognized For Cardiac Regeneration Research – WPI News
categoriaCardiac Stem Cells commentoComments Off on Professor Recognized For Cardiac Regeneration Research – WPI News | dataDecember 3rd, 2019
Read All

Global Synthetic Stem Cells Market :Industry Analysis and Forecast (2018-2026) – The Market Expedition

By daniellenierenberg

Global Synthetic Stem Cells Marketwas valued at US$ 7.97 Mn in 2017, and is expected to reach at US$ 37Mn by 2026, at CAGR of 22.62% during forecast period.

Different Applications of adult stem cells in regenerative medicines have made huge attention and interest among doctors and hospitals at large. There is huge scope for stem cells in the treatment of cardiology and neurology.

Explain and define synthetic stem cells market Forecast the synthetic stem cells market, by region Forecast the synthetic stem cells market, by application Detailed research of factors influencing on synthetic stem cells market (drivers, restraints, opportunities and challenges) Critical analysis of industry trends, prospects and contribution to the synthetic stem cells market Analysis of synthetic stem cells market for stake holders Forecasting of market size by different geographic segment of synthetic stem cells market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/22622

Driving factors that influence Synthetic Stem Cell Market include ethical values of embryonic stem cells, the risk of tumour formation and risk of rejection due to immune to natural stem cells. Stem cell work by promoting endogenous healing; that is, they heal damaged parts of tissue in repairing itself by secreting paracrine factors. While stem cell treatment is more effective, they are also linked with the same risks of both tumour growth and immune rejection. It is the major driving force for synthetic stem cells.

The largest market share of the synthetic stem cells market is occupied by cardiovascular diseases, the fact is first synthetic stem cells was invented to cure cardiac tissue.North America has a large market share of synthetic stem cells in the region. The Asia Pacific and European region have almost equal market share. Rest of the world have least market share as compared to the other regions.Key players operating in the Synthetic stem cells market are Sangamo Therapeutics, Athersys, Pluristem Therapeutics, Cellular Biomedicine Group, Vericel, BrainstormCell Therapeutics, Caladrius Biosciences, Cytori Therapeutics, Cesca Therapeutics, VistaGen Therapeutics.

The report covers total market for synthetic stem cells has been analysed based on the Porters five forces model. The impact of the different market factors, such as drivers, restraints, and opportunities, challenges key issues SWOT analysis, and technology forecasting is also illustrated in the report.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/22622

Scope of Global Synthetic Stem Cells Market:

Global Synthetic Stem Cells Market, by Application:

Cardiovascular Disease Neurological Disorders Cancer Diabetes Gastrointestinal Musculoskeletal Disorders

Global Synthetic Stem Cells Market, by Region:

North America Europe Middle East & Africa Asia Pacific South America

Key Players Operating In Global Synthetic Stem Cells Market:

Sangamo Therapeutics Athersys Pluristem Therapeutics Cellular Biomedicine Group Vericel BrainstormCell Therapeutics Caladrius Biosciences Cytori Therapeutics Cesca Therapeutics VistaGen Therapeutics

Browse Full Report with Facts and Figures of Synthetic Stem Cells Market Report at:https://www.maximizemarketresearch.com/market-report/synthetic-stem-cells-market/22622/

MAJOR TOC OF THE REPORT

Chapter One: Synthetic Stem Cells Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Synthetic Stem Cells Market Competition, by Players

Chapter Four: Global Synthetic Stem Cells Market Size by Regions

Chapter Five: North America Synthetic Stem Cells Revenue by Countries

Chapter Six: Europe Synthetic Stem Cells Revenue by Countries

Chapter Seven: Asia-Pacific Synthetic Stem Cells Revenue by Countries

Chapter Eight: South America Synthetic Stem Cells Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Synthetic Stem Cells by Countries

Chapter Ten: Global Synthetic Stem Cells Market Segment by Type

Chapter Eleven: Global Synthetic Stem Cells Market Segment by Application

Chapter Twelve: Global Synthetic Stem Cells Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email:sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more from the original source:
Global Synthetic Stem Cells Market :Industry Analysis and Forecast (2018-2026) - The Market Expedition

To Read More: Global Synthetic Stem Cells Market :Industry Analysis and Forecast (2018-2026) – The Market Expedition
categoriaCardiac Stem Cells commentoComments Off on Global Synthetic Stem Cells Market :Industry Analysis and Forecast (2018-2026) – The Market Expedition | dataDecember 3rd, 2019
Read All

Howard University athlete makes the call to donate stem cells – WTOP

By daniellenierenberg

This fall, 21-year-old Jurnee Farrell, a Howard University senior and a member of the universitys volleyball team donated stem cells to a complete stranger.

This fall, 21-year-old Jurnee Farrell, a Howard University senior and a member of the universitys volleyball team, was set to play in the Mid-Eastern Athletic Conference Tournament.

But instead, she was sidelined by a decision she made herself.

Two years ago, she signed up with Be the Match, a nonprofit that registers potential bone marrow and stem cell donors. When she got the call that she was a match for a 57-year-old woman with a form of leukemia, she was surprised.

At first I was like, This isnt real, Farrell recalled, but then said her decision was clear. She would follow through on the commitment she made two years ago when she signed up.

That meant undergoing a series of shots five days before the outpatient procedure, and then undergoing apheresis, a process in which the donor has blood removed through a needle in one arm, blood-forming cells are collected, and then the blood is returned through a needle in the other arm. The session can take up to eight hours.

Farrell said that the actual donation wasnt bad, but that the shots given in a series five days prior proved a little uncomfortable.

Nevertheless, she urges potential donors to sign up.

Its really not that bad, and the person whose life youre saving is probably going through so much more than you are, she said.

And while Farrell missed the tournament last month, shes back on the court already. We are going to the NCAA tournament this weekend, actually, and we play Pitt on Friday, she said. I just started practicing last week!

Farrells decision to register as a donor is one for which the staff at Be the Match is especially grateful.

Lauren Mueller, a public relations specialist with Be the Match, explained that for Caucasian patients waiting for a bone marrow or stem cell donation, the odds of finding a match are roughly 70%. For African-American patients, the odds are much lower, at 23%.

As a result, we are always looking to increase our diversity on the registry, said Mueller, who encourages people to consider registering.

It starts with a cheek swab, and Mueller said its not uncommon for years to go by before a potential donor hears that they might be a match, just as it was in Farrells case.

Your selfless action can help save a life, Mueller said.

Farrell said that shes hopeful her donation will prove successful, and that she would love to meet the recipient one day.

Like WTOP on Facebook and follow @WTOP on Twitter to engage in conversation about this article and others.

2019 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

Original post:
Howard University athlete makes the call to donate stem cells - WTOP

To Read More: Howard University athlete makes the call to donate stem cells – WTOP
categoriaBone Marrow Stem Cells commentoComments Off on Howard University athlete makes the call to donate stem cells – WTOP | dataDecember 3rd, 2019
Read All

Page 4«..3456..1020..»